BioVector? GLC-2 人小細(xì)胞肺癌細(xì)胞株

BioVector? GLC-2 Human Small Cell Lung Carcinoma Cell Line

第一部分 中文說明

一 產(chǎn)品基本信息與遺傳學(xué)背景

• 細(xì)胞名稱 BioVector? GLC-2 人小細(xì)胞肺癌細(xì)胞

• 別名與同義詞 GLC 2、GLC2、OC-NYH、NYH

• 系統(tǒng)學(xué) Accession Cellosaurus CVCL_8207

• 物種來源 人類 Homo sapiens

• 組織與疾病背景 該細(xì)胞株源自一名小細(xì)胞肺癌（SCLC）患者的胸腔積液轉(zhuǎn)移灶。小細(xì)胞肺癌屬于神經(jīng)內(nèi)分泌癌，惡性程度極高且早期極易發(fā)生全身廣泛轉(zhuǎn)移。

• 突變特征 帶有明確的 TP53 基因突變（第8外顯子缺失 Ex8del14），常表現(xiàn)出對(duì)多種傳統(tǒng)拓?fù)洚悩?gòu)酶抑制劑特異性的耐藥表型變化。

• 生物安全級(jí)別 1級(jí)。

二 細(xì)胞形態(tài)學(xué)與培養(yǎng)環(huán)境

• 形態(tài)學(xué)特征 展現(xiàn)典型的小細(xì)胞肺癌特征，細(xì)胞呈小圓形或短梭形。通常在培養(yǎng)基中呈松散的懸浮細(xì)胞團(tuán)塊、聚集體形式生長(zhǎng)，胞質(zhì)極少。

• 神經(jīng)樣分化潛能 在特定藥物（如星形孢素 Staurosporine）或特異性細(xì)胞外基質(zhì)成分（如層粘連蛋白 Laminin）的誘導(dǎo)干預(yù)下，該懸浮細(xì)胞能轉(zhuǎn)變?yōu)橘N壁并長(zhǎng)出長(zhǎng)軸突的神經(jīng)元樣（Neuron-like）表型。

• 生長(zhǎng)模式 懸浮聚集生長(zhǎng)。

• 倍增時(shí)間 增殖速度相對(duì)溫和，倍增時(shí)間大約為 37小時(shí)。

• 標(biāo)準(zhǔn)完全培養(yǎng)基配方

  • 基礎(chǔ)培養(yǎng)基 BioVector? RPMI-1640 培養(yǎng)基。

  • 維持添加 10% 到 15% BioVector? 優(yōu)質(zhì)胎牛血清（較高血清濃度有助于維持懸浮細(xì)胞簇的活力）。

• 物理培養(yǎng)參數(shù) 37攝氏度恒溫、5% 二氧化碳、空氣飽和濕度。

三 細(xì)胞傳代與復(fù)蘇標(biāo)準(zhǔn)操作步驟

1. 常規(guī)傳代操作

   • 當(dāng)懸浮的細(xì)胞簇生長(zhǎng)得過于緊密、龐大，或者培養(yǎng)基顯著變黃時(shí)需要進(jìn)行傳代。

   • 將包含細(xì)胞簇的懸液轉(zhuǎn)移至離心管中，以 150 g 離心 5分鐘，棄去舊培養(yǎng)基。

   • 用新鮮的 BioVector? 完全培養(yǎng)基重懸細(xì)胞。由于該細(xì)胞以細(xì)胞簇形式生長(zhǎng)，傳代時(shí)需用移液槍非常輕柔地吹打幾下，將極大的團(tuán)塊打散成較小的細(xì)胞叢，切勿過度吹打成單細(xì)胞，否則會(huì)嚴(yán)重阻礙其后續(xù)的成活增殖。

   • 傳代接種比例通常為 1比2 至 1比3。

2. 凍存細(xì)胞復(fù)蘇

   • 從液氮中取出冷凍管，立即投入 37攝氏度 BioVector? 水浴鍋中快速搖動(dòng)使其融化，控制在 2分鐘內(nèi)。

   • 將解凍的細(xì)胞懸液移至含 5 mL 預(yù)熱培養(yǎng)基的離心管中，以 150 g 離心 5分鐘。

   • 棄去含有二甲基亞砜的舊上清，加入新鮮 BioVector? 完全培養(yǎng)基重懸，直接接種到培養(yǎng)瓶?jī)?nèi)，靜置培養(yǎng)。

四 核心科研應(yīng)用方向

1. 小細(xì)胞肺癌（SCLC）靶向耐藥機(jī)制探索：BioVector? GLC-2 作為原發(fā)性小細(xì)胞肺癌的典型懸浮模型，廣泛用于研究拓?fù)洚悩?gòu)酶 II（Topoisomerase II）催化抑制劑的耐藥逃逸機(jī)制，以及小細(xì)胞肺癌對(duì)經(jīng)典順鉑加依托泊苷方案耐藥性的逆轉(zhuǎn)實(shí)驗(yàn)。

2. 腫瘤神經(jīng)內(nèi)分泌分化與可塑性機(jī)制：利用該細(xì)胞在細(xì)胞外基質(zhì)（ECM）誘導(dǎo)下向神經(jīng)元樣表型轉(zhuǎn)化的獨(dú)特性質(zhì)，用于解析小細(xì)胞肺癌在微環(huán)境重塑下發(fā)生神經(jīng)分化調(diào)控、轉(zhuǎn)錄因子網(wǎng)絡(luò)切換及軸突生長(zhǎng)相關(guān)的病理機(jī)制。

3. 新型肺癌小分子聯(lián)合用藥篩選：用于評(píng)估新型細(xì)胞周期檢查點(diǎn)抑制劑、ROS 誘導(dǎo)劑、多肽偶聯(lián)藥物（PDC）等對(duì)高度惡性神經(jīng)內(nèi)分泌肺癌細(xì)胞株的靶向清除效能。

PART 2 ENGLISH SECTION

I General Information and Genetic Background

• Cell Line Name BioVector? GLC-2

• Synonyms GLC 2, GLC2, OC-Ny, OC-NYH, NYH

• Cellosaurus Accession CVCL_8207

• Species Origin Human Homo sapiens

• Tissue and Disease Background Established from the metastatic pleural effusion sample of a patient suffering from Small Cell Lung Carcinoma (SCLC). SCLC stands as a notoriously aggressive neuroendocrine malignancy characterized by exceptional tumor growth rates and a high propensity for early systemic dissemination.

• Genomic Mutations Houses a validated homozygous TP53 gene deletion mutation (Ex8del14 variant).It is heavily utilized to dissect downstream therapeutic failure following Topoisomerase II catalytic targeting schedules.

• Biosafety Level BSL-1.

II Morphological Attributes and Cultivation Media

• Morphology Exhibits definitive SCLC characteristics including tiny round or short fusiform profiles with minimal cytoplasm. The line proliferates primarily as floating, multi-cellular suspension aggregates and clusters.

• Neuroendocrine Plasticity Upon deliberate exposure to chemical agents like Staurosporine or when cultured on specialized extracellular matrix (ECM) substrates such as Laminin, these suspension cells display phenotypic shifting, adhering firmly and extending long axon-like projections to assume a neuron-like phenotype.

• Growth Mode Suspension growth in clusters.

• Cell Doubling Interval Moderately paced, averaging approximately 37 hours under ideal baselines.

• Standard Complete Growth Medium Formulation

  • Basal Medium BioVector? RPMI-1640 medium.

  • Routine Maintenance Supplements 10% to 15% premium BioVector? Fetal Bovine Serum. Elevated serum parameters cushion suspension cell clustering viability.

• Physical Incubation Thresholds Regulated strictly at 37 degrees Celsius under an atmospheric layer of 5% Carbon Dioxide and saturated air humidity.

III Subculturing and Thawing Protocols

1. Routine Passaging Schedule

   • Subclone the network when the floating aggregates become overly dense, darkened, or when the surrounding media shows an extensive pH color shift to yellow.

   • Collect the cluster suspension into a sterile tube, pellet at 150 g for 5 minutes, and draw off the spent broth.

   • Resuspend the biomaterial in fresh BioVector? complete growth medium. Dissociate large clusters into smaller sub-aggregates by pipetting very gently several times. Do not forcefully shear the cells into absolute single units, as doing so impairs post-passage cell survival.

   • Seed fresh flasks at a recommended split ratio of 1比2 to 1比3.

2. Cryovial Thawing and Recovery

   • Retrieve the cryovial from storage and plunge it into a 37 degrees Celsius BioVector? water bath with immediate agitation until liquefied within 2 minutes.

   • Dilute the suspension into 5 mL of warm medium and spin down at 150 g for 5 minutes.

   • Decant the DMSO tainted supernatant, gently resuspend the remaining cell mass in fresh complete BioVector? medium, and plate directly into a culture vessel for undisturbed incubation.

BioVector NTCC質(zhì)粒載體菌株細(xì)胞蛋白抗體基因保藏中心

電話:400-800-2947

工作QQ/微信同號(hào):1843439339

網(wǎng)址http://www.nedfriskphoto.com